Reading time is 3 mins
.
.
OUR HAND AGAINST DIABETES HAS STRENGTHENED
Turkish professor, who has signed a scientific discovery that will revolutionize the treatment of diabetes, said that they have developed a new treatment method for treating both Type 1 and Type 2 diabetes.
Harvard Center for Metabolic Research, Prof. Dr. and his team have made a scientific discovery that will revolutionize the treatment of diabetes. Stating that hormone ‘Fabkin’, discovered as a result of research, plays an important role in the development of both Type 1 and Type 2 diabetes, Prof. Dr. told us about his 10 years of research and its results.
In the study, “How are fluctuations in the body’s energy reserves transmitted to other organs that play a metabolically critical role, and which molecules or hormones carry the signals necessary for the emergence of correct responses?” Dr., who expressed that they were looking for an answers to question, said: “We predicted that this signal would be released from fat cells, since the most important place where energy is stored is adipose tissue, and therefore we were studying the signals that these cells produce when they break down the fats they store. This process, in which the protein called FABP4, which we found ten years ago, guided us, was concluded with the discovery of a new hormone, the Fabkin complex. After FABP4 was released from fat cells, we found that it tues with two different proteins to form a new protein complex. This complex transmits news and regulates its activities through another protein located on the cell wall that senses the molecules used by living beings as energy units and regulates their activities. In summary, the hormone Fabkin has a very different structure and mechanism of action than the hormones known so far,” he said.
.
THE FIRST TARGET IS THE PANCREAS
First study the influence of the hormone insulin in the pancreas fabkin of the target cell and the release of beta cells, which have a vital role in controlling the course of diabetes who came before them as, said: “the levels of this hormone in the blood as interesting, both Type 1 and type 2 diabetes in animals of both the model and, more importantly, watching as very high in people with diabetes of both types was observed. This led us to think that there may be a common mechanism in these two types of diabetes where this hormone is out of control. In our experiments, we were able to show that beta cells are protected when we raise the levels of the FAB hormone to a normal or low range by genetic and chemical methods, they function normally, and both types of diabetes can be stopped in experimental models.”
Prof. Dr. this new presence and working of the mechanism of hormone underlining the discovery opened a whole new way to new treatments, said: “an antibody that binds to the complex in the centre developed and Fabkin models of both Type 1 and type 2 diabetes in a striking shows the effectiveness of treatment. It is with this antibody that we have shown in our article that the occurrence of the disease is prevented in type 1 diabetes, and in type 2 diabetes, it is prevented and treated. We do not yet know if there is a possibility of using Type 1 diabetes treatment. Recent studies can now determine the risk of diabetes with a very high accuracy rate. But unfortunately, despite the fact that it is known that the disease will occur in these people, no intervention can be performed. One of our main goals is to identify a measure that can be done during this period and to delay or completely stop the occurrence of the disease.”
.
TWO IMPORTANT AND DIFFICULT EXAMS
“Here, of course, there is an exam in two important and tough; first, the development of safe and active molecule, clear the way here that I can see, many other molecules in our study who work on a prototype molecular groups on this topic is going. In addition, the discovery of the working mechanism of the hormone Fabkin will pave the way for other and more creative drug applications. The second and most important stage is human applications and clinical testing. I am also very optimistic about this, and based on the information we have so far, I think that effective human interventions with the right molecules will be possible, and it may not take too long.”
.
SUCCESSFUL TEAMWORK
Prof. Dr. noted that this success is a team effort, saying, “Although I’m not the one talking here, there are many scientists’ contributions to the path that has been taken. The most important factor in the establishment and existence of the Center is that we can follow an important question in such a long process and face many failures in the realization of the Type 1 Diabetics Foundation and such long-term, unusual and intensive research,” he said.
.
.
.
.
Turkey's world-renowned organ transplant specialist. Dr. Demirbaş has 104 international publications and 102 national publications.
Physician's Resume:
Born on August 7, 1963 in Çorum, Prof. Dr. Alper Demirbaş has been continuing his work as the President of MedicalPark Antalya Hospital Organ Transplantation Center since 2008.
Prof. who performed the first tissue incompatible kidney transplant in Turkey, the first blood type incompatible kidney transplant, the first kidney-pancreas transplant program and the first cadaveric donor and live donor liver transplant in Antalya. Dr. As of August 2016, Alper Demirbaş has performed 4900 kidney transplants, 500 liver transplants and 95 pancreas transplants.
In addition to being the chairman of 6 national congresses, he has also been an invited speaker at 12 international and 65 national scientific congresses. Dr. Alper Demirbaş was married and the father of 1 girl and 1 boy.
Awards:
Eczacibasi Medical Award of 2002, Akdeniz University Service Award of 2005, Izder Medical Man of the Year Award of 2006, BÖHAK Medical Man of the Year Award of 2007, Sabah Mediterranean Newspaper Scientist of the Year Award of 2007, ANTIKAD Scientist of the Year Award of 2009, Social Ethics Association Award of 2010, Işık University Medical Man of the Year Award of 2015, VTV Antalya's Brand Value Award of 2015.
Certificates:
Doctor of Medicine Degree Hacettepe University Faculty of Medicine Ankara, General Surgeon Ministry of Health Turkey EKFMG (0-477-343-8), University of Miami School of Medicine Member of Multiple Organ Transplant, ASTS Multiorgan Transplant Scholarship. Lecturer at Kyoto University. Lecturer at University of Essen, Research assistant at the University of Cambridge .
Professional Members:
American Society of Transplant Surgeons, American Transplantation Society Nominated, Middle East and Southern Africa Council Transplantation Society 2007, International Liver Transplantation Association, Turkish Transplantation Association, Turkish Society of Surgery, Turkish Hepatobiliary Surgery Association.
Disclaimer:
Our website contents consist of articles approved by our Web and Medical Editorial Board with the contributions of our physicians. Our contents are prepared only for informational purposes for public benefit. Be sure to consult your doctor for diagnosis and treatment.
- CRANIOCERVICAL SYNDROME MISALIGNMENT IN THE UPPER CERVICAL REGION - 16/04/2024
- MISALIGNMENT OF THE UPPER CERVICAL BONES (C1-C2) - 16/04/2024
- WHAT IS GLOSSOPHARYNGEAL NEURALGIA (SORE THROAT)? - 16/04/2024